

# Appendix 4D

## Half Year Report to the Australian Securities Exchange

### Part 1

<b>Name of Entity</b>	AdAlta Limited
<b>ABN</b>	92 120 332 925
<b>Half Year Ended</b>	31 December 2016
<b>Previous Corresponding Reporting Period</b>	Half Year Ended 31 December 2015

### Part 2 – Results for Announcement to the Market

	<b>\$'000</b>	<b>Percentage increase /(decrease) over previous corresponding period</b>
<b>Revenue from continuing operations</b>	\$13	261%
<b>Loss from continuing activities after tax attributable to members</b>	\$2,266	329%
<b>Net loss attributable to members</b>	\$2,266	329%

<b>Dividends (distributions)</b>	<b>Amount per security</b>	<b>Franked amount per security</b>
<b>Final Dividend</b>	Nil	Nil
<b>Interim Dividend</b>	Nil	Nil
<b>Record date for determining entitlements to the dividends (if any)</b>	Not Applicable	

#### **Brief explanation of any of the figures reported above necessary to enable the figures to be understood:**

The Company completed a capital raising of \$10,000,000 and listed on ASX in August 2016. The funds raised have enabled further development of the Company's lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases.

### **Part 3 – Contents of ASX Appendix 4D**

<b>Section</b>	<b>Contents</b>
Part 1	Details of entity, reporting period
Part 2	Results for announcement to the market
Part 3	Contents of ASX Appendix 4D
Part 4	Commentary on results
Part 5	Details relating to dividends
Part 6	Net tangible assets per security
Part 7	Details of entities over which control has been gained or lost
Part 8	Details of associates and joint venture entities
Part 9	Information on audit or review

---

## Part 4 – Commentary on Results

Refer to the Review of Operations contained in the Directors' Report which forms part of the attached Interim Financial Report for details.

## Part 5 – Details Relating to Dividends

Date the dividend is payable	N/A
Record date to determine entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign sourced dividend or distribution	N/A
Details of any dividend reinvestment plans in operation	N/A
The last date for receipt of an election notice for participation in any dividend reinvestment plans	N/A

## Part 6 – Net Tangible Assets per Security

	2016	2015
Net tangible asset backing per ordinary security	8.2 cents	25.6 cents

## Part 7 – Details of Entities Over Which Control has been Gained or Lost

Name of entity (or group of entities)	N/A
Date control gained or lost	N/A
Contribution of the controlled entity (or group of entities) to the profit/(loss) from ordinary activities during the period, from the date of gaining or losing control	N/A
Profit (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period	N/A
Contribution to consolidated profit/(loss) from ordinary activities from sale of interest leading to loss of control	N/A

## Part 8 – Details of Associates and Joint Venture Entities

Name of entity	Ownership Interest		Contribution to net profit/(loss)	
	2015 %	2014 %	2015 \$A'000	2014 \$A'000
	N/A	N/A	N/A	N/A
Associates				
Joint Venture Entities				
Aggregate Share of Losses				

## Part 9 – Audit/Review Status

This report is based on accounts to which one of the following applies: (Tick one)			
The accounts have been audited		The accounts have been subject to review	✓
The accounts are in the process of being audited or subject to review		The accounts have not yet been audited or reviewed	

**If the accounts have not yet been audited or subject to review and are likely to be subject to dispute or qualification, a description of the likely dispute or qualification:**

Not applicable

**If the accounts have been audited or subject to review and are subject to dispute or qualification, a description of the dispute or qualification:**

Not applicable

## Attachments Forming Part of Appendix 4D

Attachment No.	Details
1	Interim Financial Report

Signed by Company Secretary

**Ian Hobson**

**Dated: 13 February 2017**



**AdAlta Limited**

**ABN 92 120 332 925**

**Half year report for the half-year ended  
31 December 2016**

# Corporate directory

## Board of Directors

Dr Paul MacLeman	Non- Executive Chairman
Ms Samantha Cobb	Managing Director
Dr James Williams	Non-Executive Director
Ms Elizabeth McCall	Non-Executive Director
Dr John Chiplin	Non-Executive Director
Dr Robert Peach	Non-Executive Director

## Company Secretary

Mr Ian Hobson

## Registered Office

Suite 15 / 2 Park Drive  
Bundoora, Victoria 3083

## Website

Website: [www.adalta.com.au](http://www.adalta.com.au)

## Auditors

Butler Settineri Pty Ltd  
Unit 16, First Floor,  
100 Railway Road  
Subiaco, Western Australia 6008

## Share Registry

Automic Registry Services  
Level 3  
50 Holt Street  
Surrey Hills, NSW 2010  
Tel: +61 2 9698 5414

## Stock Exchange

Australian Securities Exchange Ltd

## ASX Code

1AD

# Half year report for the half-year ended 31 December 2016

## Contents

Directors' report.....	1
Auditor's independence declaration.....	3
Independent auditor's review report.....	4
Directors' declaration.....	6
Condensed statement of profit or loss and other comprehensive income.....	7
Condensed statement of financial position.....	8
Condensed statement of changes in equity.....	9
Condensed statement of cash flows.....	10
Condensed notes to the financial statements.....	11

## Directors' report

The Directors of AdAlta Limited ("AdAlta" or "the Company") submit herewith the financial report of the Company for the half-year ended 31 December 2016. In order to comply with the provisions of the *Corporations Act 2001*, the directors report as follows:

### Names of Directors

The names of the Directors of the Company during or since the end of the half-year are noted below. Directors were in office for the entire period unless otherwise stated:

Dr Paul MacLeman  
Ms Samantha Cobb  
Dr James Williams  
Ms Elizabeth McCall  
Dr John Chiplin  
Dr Robert Peach (appointed 14 November 2016)

### Operating results

The loss of the Company for the half-year ended 31 December 2016, after accounting for income tax benefit, amounted to \$2,265,692. The loss after tax for the Company was \$688,415 for the half-year ended 31 December 2015. The half-year ended 31 December 2016 operating results are attributed to the following:

- Research and development expenditure of \$1,710,130 (31 December 2015: \$448,674); and
- Corporate and administration expenses of \$588,028 (31 December 2015: \$244,547).

### Review of operations

On 8 July 2016, the Company lodged a prospectus with ASIC for the offer of 32,000,000 and up to 40,000,000 ordinary fully paid shares at a price of \$0.25 per share to raise a minimum of \$8,000,000 and a maximum of \$10,000,000. On 17 August 2016, the Prospectus closed over-subscribed with the maximum of \$10,000,000 raised. The Company was admitted to the official list of the ASX on 22 August 2016.

On 11 August 2016, the Company's convertible notes and preference shares converted to ordinary shares.

On 22 August 2016, the Company received a research and development tax incentive refund of \$738,045 for the 2015/2016 financial year.

During the period, 1,110,874 unlisted options were exercised into ordinary shares and 64,122 unlisted options expired.

The increase in cash and cash equivalents, net assets, contributed equity and accumulated losses was largely the result of funding by way of the capital raising of \$10,000,000 and the Research and Development tax incentive.

On 14 November 2016, Mr Robert Peach was appointed as a Non-Executive Director.



**Overview of Company Strategy**

AdAlta's strategy is to develop its lead candidate, AD-114, to demonstrate safety and advance the lead to the clinic for treatment of fibrosis related diseases. Demonstration of the lead i-body drug candidate in the clinic is also expected to increase interest in wider applications of the i-body platform and its unique features of safety and efficacy.

AdAlta currently intends to licence the lead candidate to a pharmaceutical or biotechnology company to generate up-front, milestone payments and licensing revenues.

The i-body platform provides an opportunity for the expansion of the pipeline of i-body drug candidates in multiple therapeutic areas.

The Company plans to maximise the benefits of its i-body platform and i-body libraries through partnerships, while retaining the ability to resource and focus on its own in-house discovery and development activities. Development of additional i-body drug candidates provides potential for additional revenue, including up-front milestone payments and licensing payments.

**Subsequent events**

There has not been any matter or circumstance that has arisen since the end of the half-year that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years

**Auditor's independence declaration**

The auditor's independence declaration is included on page 3 of the half-year report.

Signed in accordance with a resolution of directors made pursuant to s.306(3) of the *Corporations Act 2001*.

On behalf of the directors



**Paul MacLeman**  
**Chairman**

13 February 2017

Melbourne, Victoria, Australia


## AUDITOR'S INDEPENDENCE DECLARATION

As lead auditor for the review of AdAlta Limited for the half year ended 31 December 2016, I declare that, to the best of my knowledge and belief, there have been:

- a) No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
- b) No contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect to AdAlta Limited during the half year ended 31 December 2016.

BUTLER SETTINERI (AUDIT) PTY LTD



MARIUS VAN DER MERWE CA  
Director

Perth  
Date: 13 February 2017

## INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF ADALTA LIMITED

### Report on the half year financial report

We have reviewed the accompanying half year financial report of AdAlta Limited ("the Company") which comprises the condensed statement of profit and loss and other comprehensive income, condensed statement of financial position as at 31 December 2016, the condensed statement of changes in equity and the condensed statement of cash flows for the half year ended on that date, notes comprising a statement of significant accounting policies and other selected explanatory notes and the directors' declaration.

### Directors' responsibility for the half year financial report

The directors are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such control as the directors determine is necessary to enable the preparation of the half year financial report that is free from material misstatement, whether due to fraud or error.

### Auditor's Responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2016 and its performance for the half year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of AdAlta Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain the assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Independence


In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

## Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half year financial report of AdAlta Limited is not in accordance with the *Corporations Act 2001* including:

- a) giving a true and fair view of the Company's financial position as at 31 December 2016 and of its performance for the half year ended on that date; and
- b) complying with Accounting Standard AASB 134: *Interim Financial Reporting* and the *Corporations Regulations* 2001.

BUTLER SETTINERI (AUDIT) PTY LTD



MARIUS VAN DER MERWE CA  
Director

Perth

Date: 13 February 2017

## Directors' declaration

The Directors declare that:

- (a) in the Directors' opinion, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- (b) in the Directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including compliance with accounting standard AASB 134 '*Interim Financial Reporting*' and giving a true and fair view of the financial position at 31 December 2016 and performance of the Company for the period ended on that date.

Signed in accordance with a resolution of the Directors made pursuant to s.303(5) of the *Corporations Act 2001*.

On behalf of the Directors

A large, stylized handwritten signature in black ink, appearing to read 'Paul MacLeman', is written over the printed name and title.

**Paul MacLeman**  
**Chairman**

13 February 2017  
Melbourne, Victoria, Australia

## Condensed statement of profit or loss and other comprehensive income for the half-year ended 31 December 2016

		Half year ended	
	Note	31 Dec 2016 \$	31 Dec 2015 \$
<b>Continuing operations</b>			
Revenue	3	12,580	4,807
Other income	3	19,886	-
Research and development expenses		(1,710,130)	(448,674)
Corporate administration expenses		(588,028)	(244,548)
<b>Loss before income tax</b>		<b>(2,265,692)</b>	<b>(688,415)</b>
Income tax benefit		-	-
<b>Loss for the period attributable to Owners of AdAlta Limited</b>		<b>(2,265,692)</b>	<b>(688,415)</b>
<b>Other comprehensive income, net of income tax</b>			
Items that will not be reclassified subsequently to profit or loss		-	-
Items that may be reclassified subsequently to profit or loss		-	-
<b>Other comprehensive income for the period, net of income tax</b>		<b>-</b>	<b>-</b>
<b>Total comprehensive loss for the period</b>		<b>(2,265,692)</b>	<b>(688,415)</b>
<b>Loss and total comprehensive loss attributable to:</b>			
Owners of AdAlta Limited		<b>(2,265,692)</b>	<b>(688,415)</b>
<b>Loss per share:</b>			
Basic and diluted (cents per share)	4	(0.028)	(0.33)

Condensed notes to the financial statements are included on pages 11 to 14.

## Condensed statement of financial position as at 31 December 2016

	Note	31 Dec 2016 \$	30 Jun 2016 \$
<b>Current assets</b>			
Cash and cash equivalents		8,777,365	485,558
Trade and other receivables		129,635	897,247
<b>Total current assets</b>		<b>8,907,000</b>	<b>1,382,805</b>
<b>Non-current assets</b>			
Property, plant and equipment		1,785	282
<b>Total assets</b>		<b>8,908,785</b>	<b>1,383,087</b>
<b>Current liabilities</b>			
Trade and other payables		543,456	178,797
Provisions		53,125	36,402
<b>Total current liabilities</b>		<b>596,581</b>	<b>215,199</b>
<b>Total liabilities</b>		<b>596,581</b>	<b>215,199</b>
<b>Net assets</b>		<b>8,312,204</b>	<b>1,167,888</b>
<b>Equity</b>			
Issued capital	5	17,560,338	8,150,331
Reserves	6	3,908	3,908
Accumulated losses		(9,252,042)	(6,986,351)
<b>Total equity</b>		<b>8,312,204</b>	<b>1,167,888</b>

Condensed notes to the financial statements are included on pages 11 to 14.

## Condensed statement of changes in equity for the half-year ended 31 December 2016

	Issued capital	Share capital Series A Preference Shares	Convertible Notes	Retained Earnings	Share based payment reserve	Total
	\$	\$		\$	\$	\$
<b>Balance at 1 July 2015</b>	<b>2,490,279</b>	<b>2,999,998</b>	<b>1,035,000</b>	<b>(5,823,295)</b>	<b>3,908</b>	<b>705,890</b>
Loss for the period	-			(688,145)	-	(688,145)
Other comprehensive income	-	-	-	-	-	-
<b>Total comprehensive loss for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(688,145)</b>	<b>-</b>	<b>(688,145)</b>
Issue of convertible notes	-		525,000	-	-	525,000
Conversion of options to shares	54	-	-	-	-	54
<b>Balance at 31 December 2015</b>	<b>2,490,333</b>	<b>2,999,998</b>	<b>1,560,000</b>	<b>(6,511,440)</b>	<b>3,908</b>	<b>542,799</b>
<b>Balance at 1 July 2016</b>	<b>2,490,333</b>	<b>2,999,998</b>	<b>2,660,000</b>	<b>(6,986,350)</b>	<b>3,908</b>	<b>1,167,888</b>
Loss for the period	-	-	-	(2,265,692)	-	(2,265,692)
Other comprehensive income	-	-	-	-	-	-
<b>Total comprehensive loss for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(2,265,692)</b>	<b>-</b>	<b>(2,265,692)</b>
Issue of ordinary shares (refer to note 5)	10,000,000	-	-	-	-	10,000,000
Conversion of options to shares (refer to note 5)	58,984	-	-	-	-	58,984
Share issue costs (refer to note 5)	(648,977)	-	-	-	-	(648,977)
Conversion of Preference Shares	2,999,998	(2,998,998)	-	-	-	-
Conversion of convertible notes	2,660,000	-	(2,660,000)	-	-	-
<b>Balance at 31 December 2016</b>	<b>17,560,338</b>	<b>-</b>	<b>-</b>	<b>(9,252,042)</b>	<b>3,908</b>	<b>8,312,204</b>

Condensed notes to the financial statements are included on pages 11 to 14.



## Condensed statement of cash flows for the half-year ended 31 December 2016

	Note	Half-year ended	
		31 Dec 2016 \$	31 Dec 2015 \$
<b>Cash flows from operating activities</b>			
Receipts from customers		-	-
Payments to suppliers and employees		(1,951,095)	(751,512)
Interest received		12,580	4,807
Research and development tax incentive		738,208	878,394
Grants received		19,724	-
<b>Net cash used in operating activities</b>		<b>(1,180,583)</b>	<b>131,689</b>
<b>Cash flows from investing activities</b>			
Payments for property, plant and equipment		(1,837)	-
<b>Net cash used in investing activities</b>		<b>(1,837)</b>	<b>-</b>
<b>Cash flows from financing activities</b>			
Proceeds from share capital	5	10,000,000	-
Proceeds from issue of convertible notes		-	525,000
Proceeds from option conversions		58,985	54
Payment of share issue costs	5	(584,757)	-
<b>Net cash provided by financing activities</b>		<b>9,474,227</b>	<b>525,054</b>
<b>Net increase in cash and cash equivalents</b>		<b>8,291,807</b>	<b>656,742</b>
Cash and cash equivalents at the beginning of the period		485,558	34,864
<b>Cash and cash equivalents at the end of the period</b>		<b>8,777,365</b>	<b>691,607</b>

Condensed notes to the financial statements are included on pages 11 to 14

# Condensed notes to the financial statements for the half-year ended 31 December 2016

## 1. Significant accounting policies

### Statement of compliance

The half-year financial report is a general purpose financial report prepared in accordance with the *Corporations Act 2001* and AASB 134 '*Interim Financial Reporting*'. The Company is a for-profit entity for financial reporting purposes under Australian Accounting Standards. The half-year report does not include notes of the type normally included in an annual financial report and shall be read in conjunction with annual financial statements of the Company for the year ended 30 June 2016 together with any public announcements made during the following half year.

The half-year financial report was authorised for issue by the Directors on 13 February 2017.

### Basis of preparation

The financial statements have been prepared on the basis of historical cost. Cost is based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars, unless otherwise noted.

The accounting policies and methods of computation adopted in the preparation of the half-year financial report are consistent with those adopted and disclosed in the Company's 2016 annual financial report for the financial year ended 30 June 2016, except for the impact of the Standards and Interpretations described below. These accounting policies are consistent with Australian Accounting Standards and with International Financial Reporting Standards.

### Significant accounting judgements and key estimates

The preparation of interim financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

### Amendments to AASBs and the new Interpretation that are mandatorily effective for the current reporting period

The Company has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to their operations and effective for the current half-year.

There were no new standards issued since 30 June 2016 that have been applied by the Company. The 30 June 2016 annual report disclosed that the Company anticipated no material impacts (amounts recognised and/or disclosed) arising from initial application of those standards issued but not yet applied at that date, and this remains the assessment as at 31 December 2016.

## 2. Segment information

The Company has identified its operating segments based on the internal reports that are used by the Board (the chief operating decision makers) in assessing performance and in determining the allocation of resources.

The Board as a whole will regularly review the identified segments in order to allocate resources to the segment and to assess its performance.

The Board considers that the Company has only operated in one segment.

Corporate costs, finance costs, and interest revenue are not considered a separate segment. The Company is domiciled and conducts its operations in Australia.

Revenues were not derived from a single external customer.

### 3. Revenue

	31 Dec 2016	31 Dec 2015
	\$	\$
Interest income	12,580	4,807
Grant income	19,724	-
Research & development tax incentive	162	-
	<b>32,466</b>	<b>4,807</b>

### 4. Loss per share

	31 Dec 2016	31 Dec 2015
	\$	\$
<b>Basic and diluted loss per share (cents per share)</b>	<b>0.0285</b>	<b>0.33</b>

The loss and weighted average number of ordinary shares used in the calculation of basic loss per share are as follows:

	31 Dec 2016	31 Dec 2015
	\$	\$
<b>Loss for the half-year attributable to the owners of the Company</b>	<b>2,265,692</b>	<b>688,415</b>

	31 Dec 2016	31 Dec 2015
<b>Weighted average number of ordinary shares for the purposes of basic and diluted loss per share</b>	<b>79,573,389</b>	<b>2,083,872</b>

### 5. Issued Capital

	31 Dec 16		30 Jun 16	
	No.	\$	No.	\$
Fully paid ordinary shares	101,110,890	17,560,338	12,418,223	2,490,333
Fully paid Series A Preference shares	-	-	2,999,998	2,999,998
Fully paid convertible notes	-	-	2,660,000	2,660,000
Balance at end of period	<b>101,110,890</b>	<b>17,560,338</b>	<b>18,078,221</b>	<b>8,150,331</b>

**Ordinary Shares**

	31 Dec 16		30 Jun 16	
	No.	\$	No.	\$
Balance at beginning of the reporting period	12,418,223	2,490,333	2,065,000	2,490,333
Issued on exercise of options	1,110,874	58,984	53,500	-
Issued as part of share split	-	-	10,299,723	-
Conversion of preference shares	21,594,477	2,999,998	-	-
Conversion of convertible notes	25,987,316	2,660,000	-	-
Issued pursuant to capital raising	40,000,000	10,000,000	-	-
Capital raising costs	-	(648,977)	-	-
Balance at end of period	<b>101,110,890</b>	<b>17,560,338</b>	<b>12,418,223</b>	<b>2,490,333</b>

**Series A Preference Shares**

	31 Dec 16		30 Jun 16	
	No.	\$	No.	\$
Balance at beginning of the reporting period	2,999,998	2,999,998	2,999,998	2,999,998
Conversion to ordinary shares	(2,999,998)	(2,999,998)	-	-
Balance at end of period	<b>-</b>	<b>-</b>	<b>2,999,998</b>	<b>2,999,998</b>

**Convertible Notes**

	31 Dec 16		30 Jun 16	
	No.	\$	No.	\$
Balance at beginning of the reporting period	2,660,000	2,660,000	2,660,000	2,660,000
Conversion to ordinary shares	(2,660,000)	(2,660,000)	-	-
Balance at end of period	<b>-</b>	<b>-</b>	<b>2,660,000</b>	<b>2,660,000</b>

Fully paid ordinary shares carry one vote per share and carry the right to dividends. Ordinary shares participate in the proceeds on winding up of the Company in proportion to the number of shares held.

**Options on issue**

<b>Expiry Date</b>	<b>Balance as at 30 June 2016</b>	<b>Exercised in the period</b>	<b>Expired in the period</b>	<b>Balance as at 31 December 2016</b>
27 September 2016	252,057	(222,061)	(29,996)	-
1 July 2018	145,976	-	-	145,976
21 September 2018	20,569	-	-	20,569
1 November 2018	381,018	(307,746)	-	73,272
1 July 2019	291,953	(127,914)	(34,126)	129,913
1 November 2019	818,378	(453,153)	-	365,225
1 November 2020	234,472	-	-	234,472
<b>Total</b>	<b>2,144,423</b>	<b>(1,110,874)</b>	<b>(64,122)</b>	<b>969,427</b>

## 6. Reserves

	31 Dec 2016 \$	30 June 2016 \$
Share based payment reserve	3,908	3,908
Total reserves at end of period	<b>3,908</b>	<b>3,908</b>

## 7. Key management personnel

Remuneration arrangements of key management personnel are disclosed in the annual financial report at 30 June 2016. During the period under review there was one change to key management personnel.

On 14 November 2016 Dr Robert Peach was appointed as Non-Executive Director and the terms of the appointment was formalised in a letter of appointment with the following key terms and conditions:

- Term of agreement – monthly until termination by the Company or until the next AGM in 2017.
- No entitlement to any compensation or damage or payment of any further director's fees for any period after termination.
- Remuneration will be \$45,000 per annum inclusive of superannuation.

Key management personnel continue to receive compensation in the form of short term employee benefits, post-employment benefits and share-based payments.

## 8. Dividends

No dividends were paid or declared for the half-year ended 31 December 2016 and the Directors have not recommended the payment of a dividend.

## 9. Commitments and contingencies

There has been no change to the commitments and contingencies disclosed in the most recent annual financial report. As at 31 December 2016, the Company has no significant commitments.

## 10. Subsequent events

There has not been any matter or circumstance that has arisen since the end of the half-year that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.